Please join our masterclass panel of experts to discuss process intensification in AAV Gene Therapy.

Demand for AAV vectors is rising with more than 550 adeno associated viral vector therapies being developed for the treatment of various disorders. As numerous biotech companies are planning to introduce these transformative gene therapies, they find themselves struggling to access financially viable AAV manufacturing yields.

In this webinar Sarah Wootton, Ph.D., (University of Guelph), Amine Kamen, Ph.D., and Jean-Simon Diallo, Ph.D. will explore current and new strategies for optimising the upstream AAV vector production process, a vital first step towards advancing gene therapies to meet clinical and commercial yields.

Tune into this free webinar to learn about:

• AAV biology and its use in cell and gene therapies
• State-of-the-art production of cell and gene therapies
• Current process intensification methods: cell line and vector engineering, media optimization, and bioreactor design to increase yields
• New strategies to properly attenuate anti-viral defences in the production system: viral sensitizer technology.

Learn more at https://xtalks.com/webinars/process-intensification-in-aav-gene-therapy/